title: Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.
abstract: The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.
authors: McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.
authors: Kaitlin
authors: K
authors: Anstett
authors: McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada.
authors: Thibault
authors: T
authors: Mesplede
authors: McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada.
authors: Maureen
authors: M
authors: Oliveira
authors: McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.
authors: Vincent
authors: V
authors: Cutillas
authors: McGill University AIDS Centre, Jewish General Hospital, Montréal, Québec, Canada Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada mark.wainberg@mcgill.ca.
authors: Mark A
authors: MA
authors: Wainberg
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics*; D004351:Drug Resistance / Q000235:genetics*; D019427:HIV Integrase / Q000235:genetics*; D019428:HIV Integrase Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000235:genetics*; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology*; D006801:Humans; D020128:Inhibitory Concentration 50; D016297:Mutagenesis, Site-Directed; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir
chemical_list: D019427:HIV Integrase; D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir
references: J Infect Dis. 2006 Sep 15;194 Suppl 1:S51-8
references: 16921473
references: Methods Mol Biol. 2009;485:427-33
references: 19020842
references: N Engl J Med. 2011 Aug 18;365(7):637-46
references: 21848464
references: J Virol. 2012 Mar;86(5):2696-705
references: 22205735
references: J Infect Dis. 2013 Mar 1;207(5):740-8
references: 23225901
references: Retrovirology. 2013;10:22
references: 23432922
references: J Antimicrob Chemother. 2015 Feb;70(2):405-11
references: 25281399
references: Clin Infect Dis. 2014 Feb;58(3):423-31
references: 24145878
references: Retrovirology. 2014;11:7
references: 24433497
references: AIDS. 2014 Mar 27;28(6):813-9
references: 24463394
references: J Antimicrob Chemother. 2014 Oct;69(10):2733-40
references: 24917583
references: J Int AIDS Soc. 2014;17(4 Suppl 3):19749
references: 25397494
references: Lancet. 2013 Aug 24;382(9893):700-8
references: 23830355